GENSCRIPT BIO(01548) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

HK Stock MarketDetailed Quotes

01548 GENSCRIPT BIO

Watchlist

12.120
-0.300-2.42%

Market Closed Mar 25 16:39 CST

26.18BMarket Cap1.14P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Trending Industry Today: GENSCRIPT BIO Leads Losses In CRO Stocks
Moomoo NewsMar 21 02:30 ET
Trending Industry Today: AKESO Leads Losses In Biotechnology Stocks
Moomoo NewsMar 21 01:30 ET
GenScript Unveils Prime Editing Boost With the Broad Institute Deal
PR NewswireMar 19 10:32 ET
Trending Industry Today: WUXI APPTEC Leads Gains In CRO Stocks
Moomoo NewsMar 17 22:30 ET
Major bank rating | Morgan Stanley: Raises GENSCRIPT BIO Target Price to HKD 21.9 and reaffirms "Shareholding" rating.
Morgan Stanley published a Research Report stating that looking ahead to 2025, the recovery trend of GENSCRIPT BIO is expected to continue, with a more optimistic operational outlook. The promotion of Global localization development strategy, an increase in CRO and CDMO orders, as well as positive progress in the Business of Baisjie are believed to pave the way for sustainable expansion in the future. The firm reaffirmed its "Shareholding" rating, with the Target Price raised from HKD 18.6 to HKD 21.9.
Gelonghui FinanceMar 17 02:20 ET
From the 2024 Earnings Reports, Kingsray (01548): Focused on core business strategy, a performance inflection point aids in value reassessment.
On the morning of March 12, Kingsray announced its annual performance for 2024.
Zhitong FinanceMar 14 04:34 ET

Comments

Moomoo AI

Mar 14, 2024 06:52

Genscript Biotech's high P/S ratio is due to its promising revenue outlook. The company's strong performance and bright future are likely to keep supporting the share price unless conditions change.

Genscript Biotech Corporation's (HKG:1548) P/S Is Still On The Mark Following 29% Share Price Bounce

Moomoo AI

Mar 8, 2024 21:06

GenScript's leadership values Dr. Liu's expertise in genome editing, chemistry, and synthetic biology for its potential to offer key insights. His addition to the SAB is anticipated to boost GenScript's platform and hasten transformative breakthroughs for patients.

Press Release: Dr. David Liu Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy

Moomoo AI

Mar 6, 2024 23:06

Dr. June joining GenScript's SAB could provide invaluable insights for their initiatives, especially in cell and gene therapy. His expertise may accelerate the development of novel therapies.

Press Release: Immunotherapy Pioneer Carl H. June, MD, Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy in Advancing Cell and Gene Therapy Breakthroughs

Spinee

Jan 17, 2024 16:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

Moomoo AI

Jan 9, 2024 14:19

Despite Genscript Biotech's promising revenue outlook, its P/S ratio isn't higher than industry peers due to potential volatility in revenue forecasts. Investors should note the company's 2 warning signs.